Novo Nordisk's oral Wegovy has reached more than 3,000 patients in its debut week, the company announced, more than doubling the launch pace of Eli Lilly's rival Zepbound injection and marking a potentially transformative moment in the red-hot weight-loss drug market.

The Danish pharmaceutical giant launched its Wegovy pill on January 5, making it the first and only oral GLP-1 receptor agonist approved for weight management in the United States. The medication is now broadly available through more than 70,000 pharmacies nationwide, including CVS, Costco, and a growing roster of telehealth providers.

A Launch That Exceeded Expectations

By comparison, Eli Lilly's Zepbound—the injectable weight-loss drug that has become Wegovy's primary competitor—reached approximately 1,300 new patients during its launch week in December 2023. Novo's ability to more than double that figure suggests intense pent-up demand for a weight-loss medication that doesn't require self-injection.

The strong launch has already boosted investor sentiment. Novo Nordisk shares have climbed 25 percent month-to-date, recovering some of the ground lost during a turbulent 2025 when supply constraints and competitive pressures weighed on the stock.

"Wegovy pill is the next chapter in our decades-long GLP-1 experience—supported by the most affordable self-pay price to date in a GLP-1 for obesity. We are prepared for a full US launch, with manufacturing well underway in our North Carolina facilities."

- Dave Moore, EVP of US Operations, Novo Nordisk

Pricing Strategy Aims for Accessibility

Novo Nordisk has taken an aggressive approach to pricing, positioning the oral Wegovy as the most accessible GLP-1 medication on the market. The starting 1.5-mg dose is priced at $149 per month—roughly $5 per day—for cash-paying patients without insurance coverage.

For commercially insured patients using manufacturer savings programs, the monthly cost could drop to as low as $25. The 4-mg maintenance dose is also available at $149 per month through April 15, after which it will rise to $199. The highest doses will cost $299 monthly.

These prices represent a significant discount compared to injectable GLP-1 medications, which can exceed $1,000 per month at list price without insurance. The accessibility-focused pricing strategy appears designed to expand the addressable market and position Novo advantageously against compounding pharmacies that have been filling the gap with off-label semaglutide preparations.

Clinical Efficacy Matches Injectable Version

The oral Wegovy's appeal isn't just convenience—clinical trials have demonstrated it delivers weight-loss results comparable to the injectable version. In the OASIS 4 trial, participants taking the 25-mg daily pill achieved 16.6 percent mean weight loss when adhering to the treatment regimen, similar to the results seen with injectable Wegovy at 2.4 mg.

The FDA approved the oral formulation in late December 2025 not only for weight management but also for reducing the risk of major adverse cardiovascular events—a crucial indication that could expand insurance coverage and Medicare eligibility.

Manufacturing Ramp-Up in North Carolina

To meet anticipated demand, Novo Nordisk has committed massive resources to its manufacturing infrastructure. The company's Clayton, North Carolina facility—where the Wegovy pills are produced—is undergoing a $4 billion expansion designed to ensure supply can keep pace with what executives expect to be explosive growth.

The investment reflects lessons learned from the company's injectable GLP-1 products, which faced prolonged supply constraints that frustrated patients and physicians alike. By front-loading manufacturing capacity, Novo hopes to avoid repeating those shortages with its oral formulation.

Market Implications

The strong launch has significant implications for both Novo Nordisk and the broader GLP-1 market:

  • Competitive pressure on Eli Lilly: Lilly's Zepbound has been gaining market share with its dual-action mechanism, but an oral alternative could shift patient preferences back toward Novo's ecosystem.
  • Compounding pharmacy disruption: The affordable pricing may reduce demand for compounded semaglutide, which has flourished during supply shortages.
  • Expansion of the addressable market: Many patients who have avoided injectable medications due to needle phobia or inconvenience may now consider treatment.
  • Insurance coverage negotiations: As oral options become available, payers may face pressure to expand coverage for weight-loss medications.

What This Means for Consumers

For the millions of Americans struggling with obesity, oral Wegovy represents a meaningful advance in treatment options. The pill eliminates the need for weekly self-injections—a barrier that has prevented many patients from pursuing GLP-1 therapy despite proven efficacy.

Patients interested in the medication can access it through traditional pharmacies, telehealth platforms like Ro, LifeMD, and Weight Watchers, or directly through NovoCare Pharmacy. Those without insurance coverage can explore cash-pay options and manufacturer savings programs through GoodRx and similar platforms.

As one endocrinologist noted: "The oral formulation removes one of the last major barriers to GLP-1 adoption. For patients who've been hesitant about injections, this changes the conversation entirely."